ARCHIVES

Von Eschenbach a “misguided choice” for FDA, House members write to HHS Secretary Leavitt. Conflicts inadequately addressed, they said.

This article is from The Cancer Letter archive.

Vol. 31 No. 37 | October 14, 2005

Download PDF Visit The Full Archive

Related Articles

I-ELCAP: NEJM And Other Journals Seek Information On The Study’s Confidential Review From Henschke And Her Employers

May 6, 2011

NIH Expands Minority Biomedical Research Training

July 11, 1975

Recompetition of $1.9 Mil. Primate Contract Approved

November 15, 1985

Burton’s Clinic Reopens; Some Insurers Reportedly Reimbursing; New York Congressman Calls For Evaluation

March 28, 1986

FDA Approves Gemzar For Ovarian Cancer, Contradicting ODAC Recommendation; Continues Agency Trend to Recognize Progression-Free Survival As An Endpoint.

July 21, 2006

Arzerra Promising For Heavily Pre-Treated CLL Patients

December 26, 2008